东宝生物(300239) - 2025 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2025 was ¥163,742,176.20, a decrease of 13.29% compared to the same period last year[5]. - Net profit attributable to shareholders was ¥11,482,207.82, down 23.10% year-on-year[5]. - The net profit after deducting non-recurring gains and losses was ¥8,620,812.63, reflecting a decline of 34.37% compared to the previous year[10]. - Total operating revenue for the current period was ¥532,797,977.19, a decrease of approximately 16% compared to ¥633,112,065.92 in the previous period[25]. - Net profit for the current period is 48,447,635.50, a decrease of 32.3% compared to 71,535,188.56 in the previous period[26]. - Operating profit for the current period is 55,378,873.91, down from 82,596,541.20, reflecting a decline of 33.0%[26]. - Total comprehensive income for the current period is 48,447,635.50, down 32.3% from 71,535,188.56 in the previous period[27]. Assets and Liabilities - The total assets at the end of the reporting period were ¥2,543,840,091.48, a decrease of 3.09% from the end of the previous year[5]. - Total liabilities decreased to ¥826,649,536.43 from ¥885,496,289.52, a decline of about 6.6%[24]. - The total assets decreased to ¥2,543,840,091.48 from ¥2,624,919,556.21, reflecting a reduction of about 3.1%[24]. - Long-term equity investments decreased to ¥13,914,675.17 from ¥15,428,520.01, a decline of approximately 9.8%[23]. Cash Flow - Cash flow from operating activities for the year-to-date was ¥61,417,693.72, an increase of 109.82%[5]. - The net cash flow from operating activities increased to ¥61,417,693.72, a rise of 109.82% compared to the previous period's ¥29,272,022.08, primarily due to higher cash received from sales[14]. - Cash flow from operating activities increased to 61,417,693.72, compared to 29,272,022.08 in the previous period, representing a growth of 109.5%[27]. - Cash flow from investing activities resulted in a net outflow of -42,377,549.85, an improvement from -134,567,469.44 in the previous period[28]. - Cash flow from financing activities was -¥18,959,353.05, with a significant increase of 263.36% from the previous period, attributed to higher cash payments for debt repayment and dividends, along with stock buyback activities[14]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 20,471, with no preferred shareholders having restored voting rights[16]. - Qingdao Guoen Technology Co., Ltd. held the largest share, owning 21.18% (125,711,022 shares) of the company[16]. - The top ten shareholders collectively hold significant stakes, with the largest shareholder having 21.18% and the smallest in the top ten holding 0.62%[16]. - The company has a repurchase account holding 10,573,400 shares, representing 1.78% of the total share capital[17]. - There were no changes in the number of preferred shareholders or significant changes in the top ten shareholders due to lending or borrowing of shares[18]. - The company reported a total of 3,962,437 restricted shares, with 116,287 shares released during the period[19]. Operating Costs and Expenses - Total operating costs decreased to ¥479,925,097.45 from ¥555,269,833.32, reflecting a reduction of about 13.5%[25]. - The company's net profit margin is under pressure due to increased operating expenses, with research and development expenses rising to ¥18,907,749.32 from ¥16,012,452.92, an increase of about 18%[25]. - Financial expenses increased by 130.70% to ¥1,137,785.38, primarily due to higher interest expenses[11]. Inventory and Receivables - Accounts receivable decreased to ¥173,096,032.96 from ¥206,201,924.73, representing a reduction of about 16%[22]. - Inventory increased significantly to ¥420,415,267.14 from ¥354,463,939.10, an increase of approximately 18.6%[22]. - The company's cash and cash equivalents decreased to ¥483,228,383.16 from ¥532,101,881.48, a decline of approximately 9.2%[22]. - The company reported a decrease in total assets impairment losses to -4,747,143.37 from -1,548,347.56, indicating a significant change in asset valuation[26].